Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Arvinas (Nasdaq: ARVN) will report fourth quarter and full year 2025 financial results on February 24, 2026.

Rhea-AI Summary

Arvinas (Nasdaq: ARVN) will report fourth quarter and full year 2025 financial results on February 24, 2026. Management will review results and provide a corporate update via a live webcast at 8:00 a.m. ET.

The webcast is available under “Events and Presentations” on Arvinas’ investor website, and a replay will be posted on www.arvinas.com after the event.

Argus Feb 17 session

-1.80% close to close Open Argus

Details

News Market Reaction – ARVN

On Feb 17, the day this news came out, ARVN closed 1.80% below the previous close.

Data tracked by StockTitan Argus for the Feb 17 session.

Historical Context

5 past events · Latest: Feb 12

5 events

1. Feb 12

   Leadership change

   24h Move

   -9.6%

   CEO transition to Randy Teel with Houston moving to consulting role.

2. Feb 10

   Industry outlook

   24h Move

   +1.1%

   Report highlighting PROTAC market growth and Arvinas partnerships.

3. Nov 26

   Conference appearance

   24h Move

   +2.5%

   Planned presentation at Piper Sandler healthcare conference.

4. Nov 24

   Clinical data update

   24h Move

   +2.2%

   Multiple SABCS presentations from vepdegestrant development program.

5. Nov 05

   Earnings and pipeline

   24h Move

   +0.3%

   Q3 2025 financials, strong cash, NDA acceptance and pipeline progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

targeted protein degradation

1 terms

targeted protein degradation medical

"a new class of drugs based on targeted protein degradation, today announced"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET.

The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Arvinas (ARVN) report Q4 and full year 2025 results?

Arvinas will report fourth quarter and full year 2025 results on February 24, 2026 at 8:00 a.m. ET. According to Arvinas, management will review results and provide a corporate update during a live webcast accessible on the investor website.

How can investors watch the Arvinas (ARVN) February 24, 2026 webcast?

Investors can watch the live webcast via the Arvinas investor site under “Events and Presentations.” According to Arvinas, the webcast begins at 8:00 a.m. ET and a replay will be posted on www.arvinas.com after the event.

Will Arvinas (ARVN) provide a replay of the February 24, 2026 webcast?

Yes. A replay will be available on the Arvinas website after the webcast concludes. According to Arvinas, the replay will be posted on www.arvinas.com under the company’s investor events and presentations section.

What will Arvinas (ARVN) cover during the February 24, 2026 webcast?

Management will review fourth quarter and full year 2025 financial results and deliver a corporate update. According to Arvinas, the presentation will summarize financial performance and provide current corporate information during the live event.

Where can shareholders find the Arvinas (ARVN) investor webcast materials after the event?

Shareholders can find the webcast replay and related presentation materials on Arvinas’ investor website. According to Arvinas, materials will be posted under “Events and Presentations” and accessible via www.arvinas.com following the webcast.